- Report
- March 2024
- 183 Pages
Global
From €3226EUR$3,374USD£2,765GBP
€3585EUR$3,749USD£3,072GBP
- Report
- March 2024
- 94 Pages
Global
From €5355EUR$5,600USD£4,589GBP
- Report
- November 2023
- 141 Pages
Global
From €2390EUR$2,499USD£2,048GBP
- Report
- February 2024
- 230 Pages
Global
From €3442EUR$3,600USD£2,950GBP
- Report
- October 2023
- 146 Pages
Global
From €3373EUR$3,528USD£2,890GBP
€3968EUR$4,150USD£3,401GBP
- Report
- August 2023
- 102 Pages
Global
From €3500EUR$3,921USD£3,104GBP
- Report
- May 2023
- 102 Pages
Global
From €3500EUR$3,921USD£3,104GBP
- Report
- July 2022
- 132 Pages
Global
From €813EUR$850USD£696GBP
- Report
- May 2023
- 140 Pages
Global
From €5737EUR$5,999USD£4,916GBP
The Immunomodulator market is a subset of the Immunosuppressive Drugs market, which is composed of drugs that suppress the immune system. These drugs are used to treat autoimmune diseases, such as rheumatoid arthritis, psoriasis, and Crohn's disease, as well as to prevent organ rejection in transplant patients. Immunomodulators are a type of immunosuppressive drug that works by modulating the immune system, rather than suppressing it. This allows the body to maintain a balance between the immune system and the disease, while still providing protection against infection.
The Immunomodulator market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more